Lynestrenol

證據等級: L5

預測適應症: 5 個

Lynestrenol: From Gynecological Conditions to Migraine with or without Aura

One-Sentence Summary

Lynestrenol (marketed as Orgametril) is a synthetic progestogen historically used for gynecological conditions including endometriosis, dysfunctional uterine bleeding, and premenstrual disorders. The TxGNN model predicts it may have utility in Migraine with or without Aura (susceptibility), with 0 clinical trials and 20 publications available — though most literature addresses epilepsy-migraine genetic comorbidity mechanisms rather than Lynestrenol’s direct therapeutic role, and the drug currently holds no marketing authorisation in the Netherlands.

Quick Overview

Item	Content
Original Indication	Gynecological conditions (progestogen class; no NL marketing authorisation on record)
Predicted New Indication	Migraine with or without Aura, susceptibility to
TxGNN Prediction Score	99.51%
Evidence Level	L4
NL Market Status	Not registered
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on established pharmacology, Lynestrenol is a synthetic progestogen structurally related to 19-nortestosterone. It is converted in vivo to norethisterone and subsequently to neuroactive metabolites — most notably allopregnanolone-like steroids — which act as positive allosteric modulators of GABA-A receptors. This raises the neuronal excitability threshold, a mechanism directly relevant to both migraine and epilepsy pathophysiology. In fact, this class of neuroactive steroids forms the basis for brexanolone, a clinically approved GABA-A modulator used in postpartum depression.

Oestrogen withdrawal is a well-established migraine trigger, particularly in the menstrual window. By maintaining stable progestogenic tone, Lynestrenol may attenuate hormonal fluctuation and thereby reduce migraine frequency — especially in women with menstrually-associated migraine. A 1963 clinical observation by Lundberg (PMID 14091721) reported direct use of Lynestrenol (Orgametril) for migraine prophylaxis, providing the earliest direct clinical signal for this hypothesis. A 2026 comparative review (PMID 41723577) further contextualises progestogens within combined oral contraceptive use for migraine management, noting the nuanced benefit-risk balance by migraine subtype.

The TxGNN rank-1 prediction specifically targets the genetically-defined subtype “migraine with or without aura, susceptibility to,” which shares genetic pathways with epilepsy (SCN1A, MTHFR variants, GABA-A receptor dysregulation). While the GABA-A modulatory mechanism of Lynestrenol’s metabolites is plausible in this genetic context, the available literature for this specific subtype predominantly characterises epilepsy genetics rather than Lynestrenol’s pharmacological activity. A direct mechanistic bridge to this genetic susceptibility variant remains to be demonstrated experimentally.

Clinical Trial Evidence

Currently no related clinical trials registered for Lynestrenol in migraine with or without aura.

Literature Evidence

The following publications are drawn from the rank-1 indication evidence set. Papers are ranked by relevance to the migraine-Lynestrenol mechanistic connection; note that several address epilepsy-migraine comorbidity at the genetic level rather than Lynestrenol directly.

PMID	Year	Type	Journal	Key Findings
33856647	2021	Review	Molecular Neurobiology	Epilepsy and migraine share genetic susceptibility (SCN1A, MTHFR), neuroinflammatory pathways, and ion channel dysfunction; therapeutic strategies applicable to both conditions discussed
23294289	2013	Genetic Cohort Study	Epilepsia	Shared genetic susceptibility between migraine and epilepsy demonstrated in the Epilepsy Phenome/Genome Project (EPGP) cohort
17460155	2007	Genetic Linkage Study	Neurology	Large Belgian family with familial occipitotemporal lobe epilepsy co-segregating with migraine with visual aura; disease locus mapped to chromosome 9q
30267335	2018	Meta-analysis	Neurological Sciences	MTHFR C677T polymorphism significantly associated with epilepsy susceptibility; supports the migraine-epilepsy genetic overlap model
34575901	2021	Review	Int J Molecular Sciences	GABA-A receptor modulation identified as a key molecular target for antiepileptogenesis; directly relevant to the proposed mechanism of Lynestrenol’s neuroactive metabolites
16201993	2005	Review	Epilepsia	Developmental changes in GABAergic and glutamatergic receptor composition drive heightened neural excitability; GABA-A subunit rearrangements described
34209535	2021	Review	Int J Molecular Sciences	Bidirectional relationship between neuroinflammation and epilepsy; shared inflammatory pathways with migraine aura pathophysiology
24076350	2014	Meta-analysis	Gene	SCN1A IVS5N+5G>A polymorphism associated with susceptibility to epilepsy with febrile seizures; SCN1A also implicated in migraine with aura
22938964	2012	Review	Handbook of Clinical Neurology	Overview of in vitro and in vivo animal models used to study epilepsy pathophysiology and drug mechanisms
28086980	2017	Review	Journal of Neuroinflammation	Post-traumatic epileptogenesis driven by neuroinflammation; inflammatory pathways overlap with cortical spreading depression in migraine aura

Directly relevant evidence from rank-2 (Migraine Disorder) — highest clinical specificity for Lynestrenol:

PMID	Year	Type	Journal	Key Findings
14091721	1963	Historical Case Series	Svenska Läkartidningen	Earliest direct clinical report: prophylactic use of Lynestrenol (Orgametril) for migraine treatment by Lundberg P.O.
41723577	2026	Comparative Review	Medical Science Monitor	Review of progestogen-containing COC components across acne, hirsutism, migraine, and dysmenorrhoea; notes that menstrual migraine may benefit from extended-cycle regimens, while migraine with aura remains a COC contraindication

Netherlands Market Information

Lynestrenol currently holds no marketing authorisation with the CBG-MEB (College ter Beoordeling van Geneesmiddelen). No RVG number is on record. The product is not available as a registered medicinal product in the Netherlands.

Historically, Lynestrenol was developed by Organon (a Dutch pharmaceutical company) and marketed as Orgametril in several European markets. Its regulatory status in neighbouring countries (Belgium, Germany, UK) may be relevant for a future cross-border authorisation or label-extension strategy.

Safety Considerations

Please refer to the SmPC (Samenvatting van de Productkenmerken) for complete safety information, as no structured warning or contraindication data was available in the current Evidence Pack.

Class-level safety note relevant to the predicted indication: Combined hormonal contraceptives (oestrogen + progestogen) are contraindicated in migraine with aura due to significantly increased thromboembolic and ischaemic stroke risk. As a progestogen-only agent, Lynestrenol theoretically carries lower thrombogenic risk, but this has not been formally evaluated for migraine with aura. For migraine with brainstem aura (rank-3 indication), the risk-benefit ratio is particularly unfavourable given the posterior circulation involvement. Any clinical investigation must prospectively characterise haemostatic effects and stroke risk.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence is currently at L4, consisting of mechanism-level hypotheses and a single historical case series (1963) with no control group. Lynestrenol holds no NL marketing authorisation, making any near-term regulatory pathway for a new indication filing particularly complex. The most compelling pharmacological signal — GABA-A modulation via neuroactive progestogen metabolites — is mechanistically plausible but unvalidated in the migraine-with-aura genetic subtype targeted by the rank-1 TxGNN prediction.

To proceed, the following is needed:

Mechanism confirmation: Formal characterisation of Lynestrenol’s neuroactive metabolite profile (allopregnanolone-type activity, GABA-A receptor binding data)
Clinical evidence: A prospective controlled trial evaluating Lynestrenol or its active metabolite norethisterone in menstrually-associated migraine; the 1963 Lundberg observation should be replicated with modern methodology
Safety evaluation: Dedicated assessment of coagulation parameters and stroke risk for the progestogen-only route in patients with migraine with aura
SmPC review: Obtain and review the SmPC from a jurisdiction where Lynestrenol is currently authorised (e.g., Belgium) to assess existing warnings and contraindications applicable to the Dutch healthcare context
Regulatory pathway assessment: Consultation with CBG-MEB on whether a new indication could be pursued under Article 29 (referral) or whether a fresh marketing authorisation application would be required, given the absence of any current NL registration
Subtype stratification: Distinguish between menstrual migraine without aura (potentially lower risk, plausible benefit) and migraine with aura (higher thrombotic risk, stricter safety standards required) before any clinical programme is designed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.